ArticleBMC medicine2024

Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Ruoshuang Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.